Novocell Announces Non-Exclusive Drug Discovery Collaboration with Pfizer
News Dec 23, 2008
Novocell, Inc. has announced that it has entered into a non-exclusive drug discovery collaboration with Pfizer giving Pfizer access to Novocell’s proprietary pancreatic progenitor cells derived from human embryonic stem (hES) cells.
Under terms of the agreement, Novocell will receive an upfront payment with additional amounts payable upon the achievement of certain technical milestones, as well as research funding.
In addition, Novocell will receive payments relating to the sale by Pfizer of any exclusive therapeutic discovered as a result of the collaboration. The duration of the research collaboration will be 2 years with the option by Pfizer to extend.
“We are very pleased to collaborate with Pfizer, an industry leading pharmaceutical company with a strategic vision about regenerative medicine. This joint opportunity takes advantage of our leading stem cell engineering technologies and Pfizer’s expertise in drug discovery, providing for innovative, regenerative therapeutics,” said Alan J. Lewis, Ph.D., President and Chief Executive Officer of Novocell.
Cell Technology Used to Treat Osteochondral Knee DefectNews
Autologous cells of stromal vascular fraction were transplanted to a 36-year-old man with the use of fibrin matrix.READ MORE
Gene Editing Technology May Improve Accuracy of Predicting Heart Disease RiskNews
Scientists may now be able to predict whether carrying a specific genetic variant increases a person’s risk for disease using gene editing and stem cell technologies.READ MORE